How big is the vulvovaginal candidiasis treatment market?

In 2027 the market for vulvovaginal candidiasis treatment is worth approximately USD 1.39 billion.

What is the anticipated CAGR of the vulvovaginal candidiasis treatment industry?

Vulvovaginal Candidiasis Treatment Market size was valued at USD 1.34 billion in 2026 and is projected to grow at a 4.17% CAGR from 2027 to 2036, attaining USD 2.02 billion by 2036.

How are new oral antifungal therapies influencing treatment adoption in the vulvovaginal candidiasis treatment market?

New oral therapies provide clinicians with additional treatment options for patients seeking convenient dosing or alternatives to topical regimens, supporting higher prescription adoption and broader routine clinical use.

Why is retail pharmacy strengthening its position in the vulvovaginal candidiasis treatment market?

Retail pharmacies offer convenient, immediate access to prescription and over-the-counter antifungal treatments, aligning with patient preferences for timely symptom relief and supporting consistent treatment fulfillment.

Why does oral treatment dominate the vulvovaginal candidiasis treatment market?

Oral treatment held 44.84% share in 2026 due to convenient dosing, systemic effectiveness, and strong physician familiarity in routine outpatient infection management.

Why is topical treatment growing faster in this market?

Topical treatment is fastest-growing as patients and clinicians prefer localized therapy that directly targets infection sites while minimizing systemic exposure and improving comfort-based treatment choices.

Why is North America the leading regional market for vulvovaginal candidiasis treatment?

North America accounted for 39.75% of the market in 2026, supported by strong healthcare access, routine diagnosis, and broad availability of prescription and over-the-counter antifungal treatments.

What factors are driving growth in the Asia Pacific vulvovaginal candidiasis treatment market?

Asia Pacific is projected to grow at a 5.13% CAGR as women's healthcare access improves, awareness increases, and expanding pharmacy distribution broadens treatment availability across the region.

Who are the major participants shaping the vulvovaginal candidiasis treatment landscape?

Major players in the vulvovaginal candidiasis treatment market include Mycovia Pharmaceuticals, Inc. (USA), Pfizer Inc. (USA), Bayer AG (Germany), Scynexis, Inc. (USA), Ferrer Internacional S.A. (Spain), Bristol Myers Squibb Company (USA), Basilea Pharmaceutica Ltd. (Switzerland), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (USA), Merck & Co., Inc. (USA).